Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as well as the interaction among these factors on disease diagnosis and treatment, short and long-term outcomes. Study type: Observational (Patient Registry) Study design: Observational Model: Cohort Time Perspective: Prospective and retrospective

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016;

• Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer;

• Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy;

• Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status;

• Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit;

• Age\>18 years;

• Provision of written informed consent.

Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Yan Xu, M.D.
maraxu@163.com
861069155039
Time Frame
Start Date: 2022-11-03
Estimated Completion Date: 2025-12
Participants
Target number of participants: 5000
Treatments
I Retrospective cohort
Diagnosis of advanced non-small cell lung cancer from 2012-2016
II Prospective cohort
Advanced non-small cell lung cancer with driver gene mutations
III Prospective cohort
Non-small cell lung cancer in immuno-therapy;
IV Prospective cohort
Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
V Prospective cohort
Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
Sponsors
Leads: Peking Union Medical College Hospital

This content was sourced from clinicaltrials.gov